Business Wire
Vertex to Participate in Upcoming March Investor Conferences
📊
AI Sentiment
Positive
6/10
- Home
- VRTX
as of 03-06-2026 3:38pm EST
$455.90
$4.92
-1.07%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 115.7B | IPO Year: | 2006 |
| Target Price: | $526.79 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 27 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 15.32 | EPS Growth: | 836.54 |
| 52 Week Low/High: | $362.50 - $519.68 | Next Earning Date: | N/A |
| Revenue: | $2,488,652,000 | Revenue Growth: | 46.20% |
| Revenue Growth (this year): | 10.79% | Revenue Growth (next year): | 10.14% |
| P/E Ratio: | 30.10 | Index: | |
| Free Cash Flow: | 3.2B | FCF Growth: | N/A |
AI-Powered VRTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.87%
69.87%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
McKechnie Duncan
Sell
EVP, Chief Commercial Officer
VRTX Mar 4, 2026
Avg Cost/Share
$475.30
Shares
2,437
Total Value
$1,158,306.10
Owned After
15,122
SEC Form 4
Bozic Carmen
Sell
EVP and CMO
VRTX Feb 27, 2026
Avg Cost/Share
$480.31
Shares
2,329
Total Value
$1,118,641.99
Owned After
37,734
SEC Form 4
Kewalramani Reshma
Sell
CEO & President
VRTX Feb 27, 2026
Avg Cost/Share
$489.75
Shares
40,000
Total Value
$19,738,854.85
Owned After
125,076
Ambrose Kristen
Sell
SVP & Chief Accounting Officer
VRTX Feb 26, 2026
Avg Cost/Share
$483.36
Shares
357
Total Value
$172,559.52
Owned After
6,624
SEC Form 4
Ambrose Kristen
Sell
SVP & Chief Accounting Officer
VRTX Feb 25, 2026
Avg Cost/Share
$486.35
Shares
223
Total Value
$108,456.05
Owned After
6,624
SEC Form 4
Tatsis Ourania
Sell
EVP, Chief Reg. & Quality Off.
VRTX Feb 25, 2026
Avg Cost/Share
$486.35
Shares
260
Total Value
$126,451.00
Owned After
46,763
SEC Form 4
Atkinson Edward Morrow III
Sell
EVP, Chief Technical Ops. Off.
VRTX Feb 25, 2026
Avg Cost/Share
$486.35
Shares
668
Total Value
$324,881.80
Owned After
18,432
SEC Form 4
Biller Jonathan
Sell
EVP and Chief Legal Officer
VRTX Feb 25, 2026
Avg Cost/Share
$486.35
Shares
945
Total Value
$459,600.75
Owned After
13,659
SEC Form 4
Sachdev Amit
Sell
EVP Chief Patient & Ext Af Off
VRTX Feb 25, 2026
Avg Cost/Share
$486.35
Shares
1,846
Total Value
$897,802.10
Owned After
55,570
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McKechnie Duncan | VRTX | EVP, Chief Commercial Officer | Mar 4, 2026 | Sell | $475.30 | 2,437 | $1,158,306.10 | 15,122 | |
| Liu Joy | VRTX | EVP and Chief Legal Officer | Mar 2, 2026 | Sell | $495.96 | 892 | $442,396.32 | 22,811 | |
| Bozic Carmen | VRTX | EVP and CMO | Feb 27, 2026 | Sell | $480.31 | 2,329 | $1,118,641.99 | 37,734 | |
| Kewalramani Reshma | VRTX | CEO & President | Feb 27, 2026 | Sell | $489.75 | 40,000 | $19,738,854.85 | 125,076 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 26, 2026 | Sell | $483.36 | 357 | $172,559.52 | 6,624 | |
| Ambrose Kristen | VRTX | SVP & Chief Accounting Officer | Feb 25, 2026 | Sell | $486.35 | 223 | $108,456.05 | 6,624 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 25, 2026 | Sell | $486.35 | 260 | $126,451.00 | 46,763 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 25, 2026 | Sell | $486.35 | 668 | $324,881.80 | 18,432 | |
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Feb 25, 2026 | Sell | $486.35 | 945 | $459,600.75 | 13,659 | |
| Sachdev Amit | VRTX | EVP Chief Patient & Ext Af Off | Feb 25, 2026 | Sell | $486.35 | 1,846 | $897,802.10 | 55,570 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 12, 2026 · 100% conf.
AI Prediction SELL
1D
-3.92%
$446.77
Act: +5.69%
5D
-5.45%
$439.69
Act: +2.40%
20D
-4.07%
$446.09
Price: $465.02 Prob +5D: 0% AUC: 1.000
0000875320-26-000034
vrtx-202602120000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202026-02-122026-02-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 12, 2026
Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter)
Massachusetts 000-19319 04-3039129
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
50 Northern Avenue Boston, Massachusetts 02210 (Address of principal executive offices) (Zip Code)
(617) 341-6100 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 12, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and twelve months ended December 31, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription of Document
99.1Press Release Dated February 12, 2026.
104Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: February 12, 2026 /s/ Jonathan Biller Jonathan Biller
Executive Vice President, Chief Legal Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0000875320-25-000230
vrtx-202511030000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 3, 2025
Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter)
Massachusetts 000-19319 04-3039129
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
50 Northern Avenue Boston, Massachusetts 02210 (Address of principal executive offices) (Zip Code)
(617) 341-6100 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 3, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription of Document
99.1Press Release Dated November 3, 2025.
104Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: November 3, 2025 /s/ Jonathan Biller Jonathan Biller
Executive Vice President, Chief Legal Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 4, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 4, 2025
0000875320-25-000213
vrtx-202508040000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202025-08-042025-08-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 4, 2025
Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter)
Massachusetts 000-19319 04-3039129
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
50 Northern Avenue Boston, Massachusetts 02210 (Address of principal executive offices) (Zip Code)
(617) 341-6100 (Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 4, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and six months ended June 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2025, the Company announced the retirement of David Altshuler, Executive Vice President and Chief Scientific Officer, effective August 1, 2026.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription of Document
99.1Press Release Dated August 4, 2025.
104Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: August 4, 2025 /s/ Jonathan Biller Jonathan Biller
Executive Vice President, Chief Legal Officer
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
Did Vertex’s (VRTX) Earnings Beat and Advancing Pipeline Just Shift Its Investment Narrative?
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Vertex Insider Sales Versus Valuation Gap Raise Investor Questions
📊
AI Sentiment
Positive
6/10
Motley Fool
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
➖
AI Sentiment
Neutral
5/10
Zacks
The Zacks Analyst Blog Highlights Broadcom, AT&T, Vertex and InterGroup
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
📈
AI Sentiment
Highly Positive
8/10
Compare VRTX vs Leading Stocks
See how VRTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.